The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils

European Journal of Pharmacology

Volumn 600, Issue 1-3, 2008, Pages 87-92

  Nordquist, Rebecca E ^a   Durkin, Sean ^a   Jacquet, Aurélie ^a   Spooren, Will ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Antipsychotic; Aprepitant; Gerbil; Locomotor activity; MK869; Neurokinin; Osanetant; SB222200; SB223412; Senktide; SR142801; Tachykinin; Talnetant

Indexed keywords

ALPHA TOCOPHEROL; APREPITANT; HALOPERIDOL; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ 3 RECEPTOR; OSANETANT; RISPERIDONE; SENKTIDE; TALNETANT; VOLINANSERIN; DRUG DERIVATIVE; DRUG VEHICLE; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR; PEPTIDE FRAGMENT; SUBSTANCE P;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG POTENTIATION; GERBIL; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANIMAL MODEL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; HYPERKINESIA; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; SPECIES DIFFERENCE; VEHICLES;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GERBILLINAE; HYPERKINESIS; INJECTIONS, INTRAVENTRICULAR; MALE; MODELS, ANIMAL; MORPHOLINES; PEPTIDE FRAGMENTS; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-3; SPECIES SPECIFICITY; SUBSTANCE P; VEHICLES;

EID: 55949117514     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.011     Document Type: Article

References (26)

1. Almeida T.A., Rojo J., Nieto P.M., Pinto F.M., Hernandez M., Martin J.D., and Candenas M.L. Tachykinins and tachykinin receptors: structure and activity relationships. Curr. Med. Chem. 11 (2004) 2045-2081
2. Ding Y.Q., Shigemoto R., Takada M., Ohishi H., Nakanishi S., and Mizuno N. Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J. Comp. Neurol. 364 (1996) 290-310
3. Humpel C., Saria A., and Regoli D. Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism. Eur. J. Pharmacol. 195 (1991) 107-114
4. Jung M., Michaud J.C., Steinberg R., Barnouin M.C., Hayar A., Mons G., Souilhac J., Emonds-Alt X., Soubrie P., and Le Fur G. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Neuroscience 74 (1996) 403-414
5. Maggi C.A. The troubled story of tachykinins and neurokinins. Trends Pharmacol. Sci. 21 (2000) 173-175
6. Malherbe P., Bissantz C., Marcuz A., Kratzeisen C., Zenner M.T., Wettstein J.G., Ratni H., Riemer C., and Spooren W. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin NK3 receptor transmembrane domains. Mol. Pharmacol. 73 (2008) 1736-1750
7. Marco N., Thirion A., Mons G., Bougault I., Le Fur G., Soubrie P., and Steinberg R. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32 (1998) 481-488
8. Medhurst A.D., Parsons A.A., Roberts J.C., and Hay D.W.P. Characterization of NK3 receptors in rabbit isolated iris sphincter muscle. Br. J. Pharmacol. 120 (1996) 93-101
9. Meltzer H., and Prus A. NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov. Today Ther. Strateg. 3 (2006) 555-560
10. Meltzer H.Y., Arvanitis L., Bauer D., Rein W., and Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatr. 161 (2004) 975-984
11. Mileusnic D., Lee J.M., Magnuson D.J., Hejna M.J., Krause J.E., Lorens J.B., and Lorens S.A. Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study. Neuroscience 89 (1999) 1269-1290
12. Nakanishi S. Mammalian tachykinin receptors. Annu. Rev. Neurosci. 14 (1991) 123-136
13. Nalivaiko E., Michaud J.C., Soubrie P., Le Fur G., and Feltz P. Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study. Neuroscience 78 (1997) 745-757
14. Nguyen-Le X.K., Nguyen Q.T., Gobeil F., Pheng L.H., Emonds-Alt X., Breliere J.C., and Regoli D. Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor. Pharmacology 52 (1996) 283-291
15. Nordquist, R.E., Algeyer, B., Pauly-Evers, M., Ozmen, L., Spooren, W., submitted for publication. Pharmacological characterization of senktide-induced tail whips.
16. Pemberton D.J., Gartlon J.E., Hill M.D.W., and Jones D.N.C. Pharmacological characterisation of senktide-induced behaviours in the guinea pig. J. Psychopharmacol. 18 (2004) A28
17. 3 receptor agonists in the guinea-pig. Br. J. Pharmacol. 116 (1995) 2496-2502
18. Sarau H.M., Griswold D.E., Potts W., Foley J.J., Schmidt D.B., Webb E.F., Martin L.D., Brawner M.E., Elshourbagy N.A., Medhurst A.D., Giardina G.A.M., and Hay D.W.P. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J. Pharmacol. Exp. Ther. 281 (1997) 1303-1311
19. Schmidlin F., Dery O., Bunnett N.W., and Grady E.F. Heterologous regulation of trafficking and signaling of G protein-coupled receptors: β-Arrestin-dependent interactions between neurokinin receptors. PNAS 99 (2002) 3324-3329
20. Seabrook G.R., Bowery B.J., and Hill R.G. Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices. Eur. J. Pharmacol. 273 (1995) 113-119
21. Spooren, W., 2005 (filed). NK-3 Receptor in vivo assay. EP 1829556.
22. Spooren W., Riemer C., and Meltzer H. NK3 receptor antagonists: the next generation of antipsychotics? Nat. Rev. Drug. Discov. 4 (2005) 967-975
23. Stoessl A.J., Dourish C.T., and Iversen S.D. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. Br. J. Pharmacol. 94 (1988) 285-287
24. 3 receptor antagonists. Eur. J. Pharmacol. 577 (2007) 78-86
25. Swiss Academy of Medical Sciences and Swiss Academy of Sciences, 1995. Ethical Principles and Guidelines for Scientific Experiments on Animals, 2nd ed. http://www.springeronline.com/sgw/cda/pageitems/document/cda_downloaddocument/0,11996,0-0-45-137181-0,00.pdf.
26. Tian G., Wilkins D., and Scott C.W. Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol. Pharmacol. 71 (2007) 902-911